AstraZeneca Rumored to Bid €176 Per Share for French Biotech Abivax Amid M&A Buzz
Abivax shares jump 6% on reports of AstraZeneca's €176-per-share offer for the French inflammatory disease drugmaker, adding to ongoing acquisition speculation.
/ 52 items
#LLY↓
Novo Nordisk's Wegovy Weight-Loss Pill Shows Promising Early Sales Data
Novo Nordisk's new Wegovy weight-loss pill records over 3,000 prescriptions in its first four days, signaling strong market entry as competition with Eli Lilly intensifies in the booming obesity treatment sector.
Texas Pharmacy Sues Eli Lilly and Novo Nordisk Over GLP-1 Weight-Loss Drug Access
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
FDA Delays Decisions on Lilly's Obesity Pill and Other Fast-Track Drug Reviews
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Eli Lilly Eyes €15 Billion Abivax Acquisition Amid Drug Success
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.